Pathologic Function – Page 2

Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal

3 months ago talkbio0Tagged Antibodies, CCN4 gene, Clinical Trials, Eli, Eli Lilly, Fibrosis, Idiopathic Pulmonary Fibrosis, licensing agreement, MTX-463

Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

3 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Numab Therapeutics Secures Additional $55 Million in Series C Funding to Advance Multi-Specific Antibody Therapies

3 months ago talkbio0Tagged Biotechnology, Immunotherapy, Inflammation, multi-specific antibodies, Neoplasms, Numab, Series C

Numab Therapeutics, Series C Funding, Multi-Specific Antibodies, Immunotherapy, Oncology, Inflammation, Biotechnology

Congress Passes Slimmed-Down Continuing Resolution, Extends Telehealth Flexibilities and Includes PBM Reform

4 months ago talkbio0Tagged Continuous, Healthcare Package, Medicaid, Medicare, PBM Reform, physiologic resolution, Telehealth Flexibilities

Continuing Resolution, Telehealth Flexibilities, PBM Reform, Healthcare Package, Medicare, Medicaid

Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema

4 months ago talkbio0Tagged allogeneic cell therapy, AURN001, Biotechnology, Clinical Development, Cornea, Corneal endothelial dysfunction, Edema, Phase 2 Clinical Trials, Vision

Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development

Aurion Biotech’s AURN001 Shows Significant Vision Improvement in Phase 1/2 Trial for Corneal Edema

4 months ago talkbio0Tagged allogeneic cell therapy, AURN001, Clinical Trials, Corneal edema, Corneal endothelial dysfunction, Regenerative Medicine

AURN001, corneal edema, corneal endothelial dysfunction, allogeneic cell therapy, regenerative medicine, clinical trial results

FDA Rejects Full Approval for AstraZeneca’s Andexxa Amid Safety Concerns

4 months ago talkbio0Tagged Andexxa, Approved, AstraZeneca, concerns, F10 wt Allele, Hemorrhage, inhibitors, reversal agent, Safety, United States Food and Drug Administration

Andexxa, AstraZeneca, FDA, full approval, safety concerns, bleeding reversal agent, FXa inhibitors

PureTech’s Deupirfenidone (LYT-100) Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Phase 2b Trial

4 months ago talkbio0Tagged decline, Fibrosis, High, Idiopathic Pulmonary Fibrosis, Lung, LYT 100, Phase 2b Trial, pirfenidone, PureTech Health, Respiratory physiology

PureTech Health, Deupirfenidone (LYT-100), Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Phase 2b Trial, ELEVATE IPF Trial, Pulmonary Fibrosis Treatment